Tebentafusp-tebn is approved for unresectable or metastatic uveal melanoma

Share This Post

March 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has been licenced by the Food and Drug Administration for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

IMCgp100-202 (NCT03070392), a randomised, open-label, multicenter trial of 378 patients with metastatic uveal melanoma, was used to assess efficacy. HLA-A*02:01 genotype positivity was necessary, as determined by a central assay. Patients were excluded if they had had prior systemic or localised liver-directed treatment. Prior oligometastatic illness surgical resection was allowed. Patients with clinically severe heart disease or untreated symptomatic brain metastases were excluded from the study.

Tebentafusp-tebn (N=252) or investigator’s choice (N=126) of pembrolizumab, ipilimumab, or dacarbazine were given to patients in a 2:1 ratio. Tebentafusp-tebn was given as an intravenous infusion every week at a dose of 20 mcg on day 1, 30 mcg on day 8, 68 mcg on day 15, and every consecutive week until disease progression or intolerable toxicity. Overall survival was the primary efficacy outcome measure (OS). Investigator-assessed progression-free survival (PFS) using RECIST 1.1 was another efficacy endpoint. Patients treated with tebentafusp-tebn had a median OS of 21.7 months (95 percent CI: 18.6, 28.6), compared to 16 months (95 percent CI: 9.7, 18.4) in the investigator’s choice arm (HR=0.51, 95 percent CI: 0.37, 0.71, p0.0001). PFS for those taking tebentafusp-tebn was 3.3 months (95 percent CI: 3, 5) and 2.9 months (95 percent CI: 2.8, 3) in the investigator’s choice arm (HR=0.73, 95 percent CI: 0.58, 0.94, p=0.0139).

Cytokine release syndrome, rash, pyrexia, pruritus, exhaustion, nausea, chills, abdominal discomfort, edoema, hypotension, dry skin, headache, and vomiting were the most prevalent side effects (30%). Reduced lymphocyte count, increased creatinine, increased glucose, increased aspartate aminotransferase, increased alanine aminotransferase, decreased haemoglobin, and decreased phosphate were the most prevalent laboratory abnormalities (50 percent).

The recommended tebentafusp-tebn dose administered intravenously is:

  • 20 mcg on day 1,
  • 30 mcg on day 8,
  • 68 mcg on day 15, and
  • 68 mcg once weekly thereafter.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟